Jason Grenfell-Gardner

Jason Grenfell-Gardner is the founder of J. Molner AS, an Estonia-based generic pharmaceutical development and marketing company focused on specialty generics for the United States and Canada. He has held senior leadership roles across operations, corporate and business development, sales and marketing, and strategy within the global pharmaceutical industry.

Jason founded J. Molner in 2020 to accelerate the development of a pipeline of specialty generics, building on Estonia’s strong base of chemistry and natural sciences talent. Prior to this, he served as CEO of Teligent from 2012 until February 2020, where he led the company’s turnaround and refocused the business on the commercialization of its generic pharmaceutical pipeline. Before joining Teligent, Jason held a range of senior roles at Hikma Pharmaceuticals, a London-listed international generic pharmaceutical company, and its U.S. subsidiary, West-Ward Pharmaceuticals.

Earlier in his career, Jason worked in investment banking in Central and Eastern Europe with Trigon Capital in Tallinn, Estonia. During this period, he worked across multiple industries, including pharmaceuticals, and served as Chairman of the Board of Sanitas Pharmaceuticals in Lithuania. He has also served on the boards of PAS Gutta (Latvia – FMCG) and A/S In Your Pocket (Czech Republic – New Media), and was President of the American Chamber of Commerce in Estonia. Through these roles, he has developed extensive experience in board governance, business growth, international expansion, financial complexity, and corporate turnaround and restructuring.

Jason holds an MA (Hons) in Economics from the University of St Andrews and an MBA from INSEAD, where he studied in France and Singapore. He speaks French fluently and is conversant in Russian and Estonian, with a working knowledge of German.